UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 449

Sortiert nach

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries

PloS one, 2016-06, Vol.11 (6), p.e0157957-e0157957

2016

Link zum Volltext

Verfügbarkeit prüfen

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

The New England journal of medicine, 2016-06, Vol.374 (25), p.2419-2429

2016

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

The lancet oncology, 2015-12, Vol.16 (16), p.1617-1629

2015

Link zum Volltext

Verfügbarkeit prüfen

Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Journal of clinical oncology, 2008-01, Vol.26 (3), p.455-462

2008

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study

Haematologica (Roma), 2022-02, Vol.107 (2), p.500

2022

Link zum Volltext

Verfügbarkeit prüfen

Noncanonical β-catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia

Blood, 2023-03, Vol.141 (13), p.1597-1609

2023

Link zum Volltext

Verfügbarkeit prüfen

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

Journal of clinical oncology, 2017-11, Vol.35 (31), p.3529-3537

2017

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes

European journal of haematology, 2015-06, Vol.94 (6), p.463-463

Carella, Angelo M.

2015

Link zum Volltext

Verfügbarkeit prüfen

Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi

British journal of haematology, 2012-02, Vol.156 (3), p.346-353

2012

Link zum Volltext

Verfügbarkeit prüfen

Autophagy in blood cancers: biological role and therapeutic implications

Haematologica (Roma), 2013-09, Vol.98 (9), p.1335-1343

2013

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Blood, 2016-06, Vol.127 (23), p.2833-2840

2016

Link zum Volltext

Verfügbarkeit prüfen

Leukemia‐associated immunophenotypes subdivided in “categories of specificity” improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia

Cytometry. Part B, Clinical cytometry, 2020-05, Vol.98 (3), p.216-225

2020

Link zum Volltext

Verfügbarkeit prüfen

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

The Lancet (British edition), 2002-06, Vol.359 (9323), p.2065-2071

2002

Link zum Volltext

Verfügbarkeit prüfen

Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced‐stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi

British journal of haematology, 2015-05, Vol.169 (4), p.544-551

2015

Link zum Volltext

Verfügbarkeit prüfen

Management of early stage chronic myeloid leukemia: state-of-the-art approach and future perspectives

Current cancer drug targets, 2013-09, Vol.13 (7), p.749

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 449

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(406)
Mit Volltextzugriff
(403)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(254)
Life Sciences & Biomedicine
(245)
Humans
(227)
Hematology
(152)
Female
(146)
Male
(141)
Middle Aged
(141)
Adult
(122)
Oncology
(100)
Aged
(91)
Biological And Medical Sciences
(58)
Medical Sciences
(57)
Treatment Outcome
(57)
Adolescent
(52)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(48)
Aged, 80 And Over
(37)
Hematopoietic Stem Cell Transplantation
(37)
Transplantation, Autologous
(32)
Young Adult
(31)
Retrospective Studies
(30)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(117)
Leukemia & Lymphoma
(30)
Haematologica
(26)
British Journal Of Haematology
(23)
Journal Of Clinical Oncology
(14)
Biology Of Blood And Marrow Transplantation
(11)
Bone Marrow Transplantation
(8)
Leukemia Research
(8)
Annals Of Hematology
(6)
Acta Haematologica
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study

Noncanonical β-catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes

Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi

Autophagy in blood cancers: biological role and therapeutic implications

Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Leukemia‐associated immunophenotypes subdivided in “categories of specificity” improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma

Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced‐stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi

Management of early stage chronic myeloid leukemia: state-of-the-art approach and future perspectives

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

Suchergebnisse filtern